Search Results - "Knoblauch, Poul"

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors by STEELE, Nicola L, PLUMB, Jane A, DEBONO, Johann S, VIDAL, Laura, TJØRNELUND, Jette, KNOBLAUCH, Poul, RASMUSSEN, Annie, CHEAN ENG OOI, BUHL-JENSEN, Peter, BROWN, Robert, EVANS, T. R. Jeffry

“…Purpose: To determine the safety, dose-limiting toxicity, maximum tolerated dose, and pharmacokinetic and pharmacodynamic profiles of the novel hydroxamate…”
Get full text

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas by Vitfell-Rasmussen, Joanna, Judson, Ian, Safwat, Akmal, Jones, Robin L., Rossen, Philip Blach, Lind-Hansen, Maja, Knoblauch, Poul, Krarup-Hansen, Anders

“…Background. Belinostat is a novel histone deacetylase inhibitor. Primary Objectives. Maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of…”
Get full text

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study by O'Connor, Owen A, Horwitz, Steven, Masszi, Tamás, Van Hoof, Achiel, Brown, Peter, Doorduijn, Jeannette, Hess, Georg, Jurczak, Wojciech, Knoblauch, Poul, Chawla, Shanta, Bhat, Gajanan, Choi, Mi Rim, Walewski, Jan, Savage, Kerry, Foss, Francine, Allen, Lee F, Shustov, Andrei

“…Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted standard of care for patients with…”
Get full text

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma by Foss, Francine, Advani, Ranjana, Duvic, Madeleine, Hymes, Kenneth B., Intragumtornchai, Tanin, Lekhakula, Arnuparp, Shpilberg, Ofer, Lerner, Adam, Belt, Robert J., Jacobsen, Eric D., Laurent, Guy, Ben‐Yehuda, Dina, Beylot‐Barry, Marie, Hillen, Uwe, Knoblauch, Poul, Bhat, Gajanan, Chawla, Shanta, Allen, Lee F., Pohlman, Brad

“…Summary Belinostat is a pan‐histone deacetylase inhibitor with antitumour and anti‐angiogenic properties. An open label, multicentre study was conducted in…”
Get full text

Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial by Hainsworth, John D., Daugaard, Gedske, Lesimple, Thierry, Hübner, Gerdt, Greco, F. Anthony, Stahl, Michael J., Büschenfelde, Christian Meyer Zum, Allouache, Djelila, Penel, Nicolas, Knoblauch, Poul, Fizazi, Karim S.

“…BACKGROUND The objective of this study was to evaluate the efficacy of belinostat, a histone deacetylase inhibitor, when added to paclitaxel/carboplatin in the…”
Get full text

A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS) by Vitfell-Rasmussen, Joanna, Lind-Hansen, Maja, Safwat, Akmal, Rossen, Philip, Knoblauch, Poul, Jones, Robin L, Judson, Ian Robert, Krarup-Hansen, Anders

“…Abstract only…”
Get full text

Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies by Zain, Jasmine M., Foss, Francine M., Diefenbach, Catherine S., Petrylak, Daniel, Narwal, Ameet, Neylon, Ellen, Knoblauch, Poul, O'Connor, Owen A.

“…Abstract 3710 Belinostat (Bel) is a pan class I/II histone deacetylase inhibitor with broad preclinical activity. A phase I study of oral Bel in patients (pts)…”
Get full text

A phase I/II clinical trial of belinostat by Safwat, Akmal, Jones, Robin L, Rossen, Philip Blach, Krarup-Hansen, Anders, Judson, Ian, Vitfell-Rasmussen, Joanna, Knoblauch, Poul, Lind-Hansen, Maja

“…Background. Belinostat is a novel histone deacetylase inhibitor. Primary Objectives. Maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of…”
Get full text

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial by O'Connor, Owen A., Masszi, Tamás, Savage, Kerry J., Pinter-Brown, Lauren C., Foss, Francine M., Popplewell, Leslie, Cashen, Amanda F., Doorduijn, Jeanette, Chawla, Shanta, Knoblauch, Poul, Zinzani, Pier Luigi, Brown, Peter, Hess, Georg, Van Hoof, Achiel, Horwitz, Steven M., Shustov, Andrei R.

“…Abstract only 8507 Background: Therapies approved in US for R/R PTCL have overall response rates (ORR) of 25%-27%. The need for new therapies persists. BELIEF…”
Get full text

Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies by Zain, Jasmine M., Foss, Francine M, de Bono, Johann S., Narwal, Ameet, Neylon, Ellen, Blumenschein, George, Lassen, U., Knoblauch, Poul, Diefenbach, Catherine S., O'Connor, Owen A.

“…Abstract 1787 Belinostat (Bel) is a histone deacetylase inhibitor with broad preclinical activity. A phase I study of oral Bel in patients (pts) with solid…”
Get full text

Actions to improve the quality of data and data-handling in cancer clinical trials (CCT) by Knoblauch, Poul, Rasmussen, Annie

Get full text